文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

西欧大陆转甲状腺素蛋白心脏淀粉样变:THAOS研究解读

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).
PubMed 文献 · Eur Heart J · 2022-01-01

基于THAOS纵向观察性调查,纳入西欧九国1411例症状性ATTR淀粉样变患者(ATTRm 1286例,ATTRwt 125例),描述其表型与基因型分布。心脏表型者室间隔厚度中位数18 mm、LVEF<50%发生率38.1%,均显著高于混合表型;心脏突变或ATTRwt患者生存率更低。

要点

  • ATTR淀粉样变在西欧基因型与表型高度异质,呈地域分布差异。
  • Val122Ile、Leu111Met、Thr60Ala、Ile68Leu及ATTRwt以心脏表型为主。
  • 心脏表型者室间隔更厚、LVEF<50%更常见,生存率低于其他类型。

核心结论

  • 西欧大陆ATTR淀粉样变基因型与表型高度异质,部分亚组以心脏表型为主,临床可模拟肥厚型心肌病。

研究设计与样本

  • THAOS为正在进行的全球性纵向观察性调查,截至数据截止纳入西欧九国1411例症状性ATTR淀粉样变患者(ATTRm 1286例,ATTRwt 125例)。

主要发现

  • 心脏表型(n=210)较混合表型(n=298)室间隔厚度中位数更高[18(16-21)vs. 16(13-20)mm,P=0.0006]。
  • 心脏表型者LVEF<50%发生率更高(38.1% vs. 17.5%,P=0.0008)。
  • 心脏突变或ATTRwt(或心脏/混合表型)患者生存率低于其他基因型(或神经表型)类别(P<0.0001)。

关键数值与推荐

  • 心脏表型定义为以对称性左室肥厚、舒张期左室尺寸与容积正常、LVEF轻度降低为特征。

临床怎么用

  • 认识ATTR淀粉样变的地域性表型分布及心脏表型亚组,有助于提高对这一诊断不足疾病的临床识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Transthyretin amyloidosis (ATTR amyloidosis) is a heterogeneous disorder with cardiac, neurologic, and mixed phenotypes. We describe the phenotypic and genotypic profiles of this disease in continental Western Europe as it appears from the Transthyretin Amyloidosis Survey (THAOS). METHODS AND RESULTS: THAOS is an ongoing, worldwide, longitudinal, observational survey established to study differences in presentation, diagnosis, and natural history in ATTR amyloidosis subjects. At data cut-off, 1411 symptomatic subjects from nine continental Western European countries were enrolled in THAOS [1286 hereditary (ATTRm) amyloidosis; 125 wild-type ATTR (ATTRwt) amyloidosis]. Genotypes and phenotypes varied notably by country. Four mutations (Val122Ile, Leu111Met, Thr60Ala, and Ile68Leu), and ATTRwt, were associated with a mainly cardiac phenotype showing symmetric left ventricular (LV) hypertrophy, normal diastolic LV dimensions and volume, and mildly depressed LV ejection fraction (LVEF). Morphologic and functional abnormalities on echocardiogram were significantly more severe in subjects with cardiac (n'= 210), compared with a mixed (n = 298), phenotype: higher median (Q1-Q3) interventricular septal thickness [18 (16-21) vs. 16 (13-20) mm; P = 0.0006]; and more frequent incidence of LVEF <50% (38.1 vs. 17.5%; P = 0.0008). Subjects with cardiac mutations or ATTRwt (or cardiac or mixed phenotype) had a lower survival rate than subjects in other genotype (or the neurologic phenotype) categories (P < 0.0001, for both). CONCLUSION: ATTR amyloidosis genotypes and phenotypes are highly heterogeneous in continental Western Europe. A geographic map of the different disease profiles and awareness that a subset of subjects have a dominant cardiac phenotype, mimicking hypertrophic cardiomyopathy, at presentation can facilitate the clinical recognition of this underdiagnosed disease. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00628745.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2022. PMID: 30938420. doi:10.1093/eurheartj/ehz173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。